Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4443170 | 0.89 | CRHR1 (0.82) | CRHR1 | |
| SCHEMBL4436255 | 0.89 | CRHR1 (0.80) | CRHR1 | |
| SCHEMBL5571426 | 0.88 | CRHR1 (0.82) | CRHR1 | |
| SCHEMBL5568087 | 0.88 | CRHR1 (0.80) | CRHR1 | |
| SCHEMBL5569360 | 0.86 | CRHR1 (0.82) | CRHR1 | |
| SCHEMBL5571436 | 0.85 | CRHR1 (0.80) | CRHR1 | |
| SCHEMBL5569043 | 0.84 | CRHR1 (0.81) | CRHR1 | |
| SCHEMBL3235198 | 0.84 | CRHR1 (0.72) | CRHR1 | |
| SCHEMBL6225789 | 0.81 | CRHR1 (0.76) | CRHR1 | |
| SCHEMBL5252276 | 0.80 | CRHR1 (0.82) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023757-A1 | PROCESS FOR PREPARING BICYCLIC COMPOUNDS | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2009-01-22 | — | — | US | claimed |
| CN-101218240-A | Process for preparing bicyclic compounds | SB PHARMCO INC (PR) | 2008-07-09 | — | — | CN | claimed |
| US-20070219232-A1 | Chemical Compounds | GLAXO GROUP LIMITED | 2007-09-20 | — | — | US | claimed |
| US-20070066640-A1 | Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-03-22 | — | — | US | claimed |
| EP-1425280-B1 | HETERO-BICYCLIC CRF ANTAGONISTS | GLAXO GROUP LTD (GB) | 2006-08-30 | — | — | EP | claimed |
| US-20040171607-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2004-09-02 | — | — | US | claimed |
| CN-1525972-A | Hetero-bicyclic crf antagonists | — | 2004-09-01 | — | — | CN | claimed |
| US-20090023757-A1 | PROCESS FOR PREPARING BICYCLIC COMPOUNDS | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2009-01-22 | — | — | US | disclosed |
| CN-100447141-C | Heterobicyclic CRF antagonists | GLAXO GROUP LTD (GB) | 2008-12-31 | — | — | CN | disclosed |
| CN-101218240-A | Process for preparing bicyclic compounds | SB PHARMCO INC (PR) | 2008-07-09 | — | — | CN | disclosed |
| US-20070219232-A1 | Chemical Compounds | GLAXO GROUP LIMITED | 2007-09-20 | — | — | US | disclosed |
| US-7253284-B2 | Chemical compounds | GIAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1583531-B1 | HETEROARYL-SUBSTITUTED PYRROLO[2, 3- B]PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO INC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20070066640-A1 | Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-03-22 | — | — | US | disclosed |
| EP-1695974-A1 | 1,8-Naphthyridines as CRF antagonists | GLAXO GROUP LIMITED (GB) | 2006-08-30 | — | — | EP | disclosed |
| EP-1425280-B1 | HETERO-BICYCLIC CRF ANTAGONISTS | GLAXO GROUP LTD (GB) | 2006-08-30 | — | — | EP | disclosed |
| EP-1583531-A1 | HETEROARYL- SUBSTITUTED PYRROLO' 2, 3- B! PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | SB Pharmco Puerto Rico Inc (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20040171607-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
| CN-1525972-A | Hetero-bicyclic crf antagonists | — | 2004-09-01 | — | — | CN | disclosed |
| WO-2004062665-A1 | HETEROARYL- SUBSTITUTED PYRROLO` 2, 3- B! PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066640-A1 | Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885 |
| US-20040171607-A1 | Chemical compounds | CBR3, CBR1, CYP2B6 | CRHR1 52/4885 |
| US-20070219232-A1 | Chemical Compounds | CBR3, CBR1, HCAR3 | CRHR1 30/4885 |
| US-20090023757-A1 | PROCESS FOR PREPARING BICYCLIC COMPOUNDS | CRH, CRHR1, CRHR2 | CRHR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.